Under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company, the drugmaker has launched an I.V. injection formulation, AKYNZEO I.V. The drug AKYNZEO I.V is used to prevent chemotherapy-induced nausea and vomiting (CINV). It is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg) available as an I.V. injection ready to dilute. It is given as a single infusion 30 minutes before the start of each chemotherapy cycle to help prevent both acute and delayed CINV. The drug is already available in the EU, the United States, and Australia.
Glenmark has a strong reputation in India for being the first to introduce new and effective prophylactic treatment options for CINV among cancer patients. Aprecap (Aprepitant capsules), the first NK1 receptor blocker, was introduced around two decades ago, and Aprecap I.V. injection was introduced a few years later. Glenmark then launches AKYNZEO oral capsules in 2018, the first and only CINV prevention therapy to prevent both the acute and delayed phases of CINV with a single dose.